DRTS Stock Analysis: Buy, Sell, or Hold?
DRTS - Alpha Tau Medical Ltd. Ordinary Shares
$12.90
-0.58 (-4.30%)
▼
5d:
-1.98%
30d:
-11.16%
90d:
+3.2%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 19, 2026
26d
Get Alerted When DRTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DRTS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DRTS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DRTS is currently trading at $12.90, which is considered oversold relative to its 30-day fair value range of $13.66 to $15.22.
Technical Outlook: Technically, DRTS is in a strong uptrend. Immediate support is located at $11.99, while resistance sits at $14.50. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: DRTS scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $17.80 (+38.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DRTS is in a strong uptrend. Immediate support is located at $11.99, while resistance sits at $14.50. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: DRTS scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $17.80 (+38.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.66 -
$15.22
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 38.0% below Wall St target ($17.80)
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$13.66 -
$15.22
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$11.99
Resistance Level
$14.50
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-24.13
Wall Street Target
$17.80
(+38.0%)
Share & Embed Analysis
Last updated: October 23, 2026 6:23 AM ET
Data refreshes hourly during market hours. Next update: 7:23 AM
Data refreshes hourly during market hours. Next update: 7:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 66 BUY |
